Monte Rosa Therapeutics recorded a Q1 net loss of $0.45 per share, significantly wider than the $0.28-per-share loss analysts had anticipated and in stark contrast to the $0.57-per-share profit delivered in Q1 2025.

First-quarter revenue failed to meet consensus forecasts, highlighting softer top-line performance and raising questions about the pace of commercial adoption through its clinical-stage pipeline.